Rubicon Research Acquires Impopharma Canada

Neighbourly Pharmacy Acquires Rubicon Pharmacies for $435M

March 10, 2022

Healthcare Services

Neighbourly Pharmacy Inc. agreed to acquire Rubicon Pharmacies for CAD $435 million, adding 100 retail pharmacy locations and more than 1,500 employees. The deal, which materially increases Neighbourly's pro‑forma revenues and EBITDA, will be partially financed via a CAD $130 million public subscription receipt offering and a CAD $120 million private placement by Persistence Capital Partners (Neighbourly's largest shareholder).

Rubicon Founders Acquires Majority Stake in Horizon Infusions

February 7, 2025

Healthcare Services

Rubicon Founders has made a majority investment in Horizon Infusions, Ohio’s largest network of ambulatory infusion centers, with BroadOak Capital remaining as a minority investor. The investment will support Horizon’s growth from its 21 centers in Ohio and enable expansion into new markets while preserving the company’s patient-centered, outpatient infusion model.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

Noramco Acquires Cambrex Drug Product Business Unit (Halo Pharmaceuticals)

November 2, 2023

Pharmaceuticals

Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.

PharmaCorp Rx Inc. Completes Acquisition of a Pharmacy in Western Canada

August 7, 2025

Healthcare Services

PharmaCorp Rx Inc. (TSXV: PCRX) completed the purchase of a 100% interest in an independent pharmacy located in Western Canada for CAD 2,400,000, funded with cash on hand. The deal is the company's fourth completed pharmacy acquisition and is being executed in conjunction with its strategic alliance with PharmaChoice Canada to grow PharmaCorp's network of bannered community pharmacies.

PharmaCorp Rx Inc. Acquires Pharmacy in Atlantic Canada

October 2, 2024

Healthcare Services

PharmaCorp Rx Inc. (TSXV: PCRX) completed the acquisition of a 100% interest in a pharmacy business, including the associated land and buildings, located in Atlantic Canada for an aggregate purchase price of $15,377,013. The transaction was financed with $15,177,013 in cash and $200,000 in common shares and expands PharmaCorp’s roll-up of independent PharmaChoice Canada-affiliated pharmacies.